Urologic Oncology   

Are there specific AR Pathway inhibitors that can be crushed and used through feeding tube or would you just avoid ARPIs in such patients?

How do you decide between ureteral stent and percutaneous nephrostomy for decompression?

How does time since radiation, original PSA and grade group/gleason score inform your decision? 

FDG PET, Axumin PET, Bone scan? Or just proceed with salvage ADT/RT?

Which patients specifically benefit from both mpMRI and PET-PSMA?

Has this recent retrospective analysis published in Lancet Oncology changed your practice?

Will you use it rather than a carboplatin-containing regimen?

Based on GI regimen or urothelial carcinoma regimens?

How would you treat such a patient? 

Confirmed no urothelial carcinoma and muscle in specimen without involvement. 

Does this raise concerns about the efficacy of adjuvant immune checkpoint inhibition? Are any preliminary results from AMBASSADOR (adjuvant pembrolizu...

The forest plot from CheckMate 274 did not show a benefit for such patients? How would you select between adjuvant chemotherapy and adjuvant nivoluma...

Is a 3 month delay too long in someone who had postoperative complications?

Are there other high or very high risk features that would also contribute to your decision making?

GS 4+4. PSA low (1-2). CT and bone scan negative for lymphadenopathy or metastatic disease.  Prostate MRI pending. 

What neoadjuvant or adjuvant therapy would you give?

Should cystectomy remain standard of care? (Recently debated in JAMA Oncology: http://jamanetwork.com/journals/jamaoncology/article-abstract/2520055...

Is there a role for salvage LN dissection or salvage RT to the node? And is there a role for systemic therapy (ADT or chemotherapy) in addition? If yo...